Skip to main content

Table 1 Demographics and clinical characteristics of the subjects

From: Altered expressions of CXCR4 and CD26 on T-helper lymphocytes in hereditary hemorrhagic telangiectasia

  HHT (n = 36) Controls (n = 18)  
Age (mean, SD) 60.2 (10.4) 59.7 (10.2) p = 0.868
Sex (males, %) 26 (72%) 13 (72%) p = 1
History of severe infection (n, %) 18 (50%) 0 (0%)  
Mutation (n, %):
 ENG 18 (50%)   
 ACVRL1 16 (44%)   
 SMAD4 0 (0%)   
 Not identified 2 (6%)   
Visible telangiectases (median, min–max) 70 (0–242)   
Epistaxis frequency1 (n, %)
 Daily 13 (36%)   
 Weekly 13 (36%)   
 Monthly or more rarely 10 (28%)   
Arteriovenous malformations (n, %2)
 Lung3 12 (34%)   
 Digestive tract 19 (73%)   
 Liver 15 (44%)   
 Brain 6 (25%)   
Treatment (n, %)
 IV iron or blood transfusion (at least 5) 20 (56%)   
 Tranexamic acid 6 (17%)   
 Bevacizumab 4 (11%)   
  1. n: Number of patients
  2. 1During the last month before blood sampling
  3. 2% of patients with a screening performed for the specified organ
  4. 3Only those large enough to be considered for treatment (usually diameter of the feeding artery > 3 mm)